BNT327, BioNTech’s PD-L1xVEGF-A bispecific antibody, is a clinically advanced investigational immunotherapy candidate with the potential to surpass current checkpoint inhibitor outcomes and set a new standard of care in multiple tumor typesThe co-development and co-commercialization collaboration with a 50/50 profit/loss split will leverage both partners’ expertise, resources and global footprint to accelerate BNT327’s path towards potential regulatory approvals and market launchesBioNTech and Bristol Myers ...

Atacicept ORIGIN Phase 3 trial met the primary endpoint of reduction in proteinuria (UPCR) at week 36; participants receiving atacicept achieved a 46% reduction from baseline and 42% reduction compared to placebo at week 36 (p<0.0001)Other prespecified endpoints achieved similar or better results compared to the ORIGIN Phase 2b clinical trial — per FDA guidance, Vera is not sharing eGFR results at this time while the ORIGIN 3 placebo-controlled trial continuesThe safety profile of atacicept was favorable, a ...

VANCOUVER, British Columbia, June 02, 2025 (GLOBE NEWSWIRE) -- First Atlantic Nickel Corp. (TSXV: FAN) (OTCQB: FANCF) (FSE: P21) (“First Atlantic” or the “Company”) is pleased to announce its participation at the Benchmark Mineral Intelligence GIGA USA 2025 conference, taking place June 3-4, 2025, in Washington, DC. The Company will participate in strategic meetings during this critical mineral conference to demonstrate how its Atlantic Nickel Project addresses the growing need for nickel mining that can be ...

YUTREPIA now available to be prescribed to patients via specialty pharmaciesFDA approved YUTREPIA on May 23, 2025Court denies United Therapeutics’ request for preliminary injunction and a temporary restraining order, clearing the path for full commercial launch MORRISVILLE, N.C., June 02, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, today announced that Liquidia is scheduled to make i ...

Atlanta, June 02, 2025 (GLOBE NEWSWIRE) -- Piedmont Office Realty Trust, Inc. ("Piedmont” or “the Company") (NYSE:PDM), an owner of Class A office properties located primarily in the Sunbelt, announced today, that the Company is participating in this week’s Nareit REITWeek Investor Conference in New York City. The Company has completed over 500,000 square feet of leasing thus far in the second quarter, with 350,000 square feet related to new tenants. Approximately 70% of the new tenant leases are for curren ...

Proceeds to Support Company’s Strategic Focus on Data Center BusinessLAS VEGAS, June 02, 2025 (GLOBE NEWSWIRE) -- Hyperscale Data, Inc. (NYSE American: GPUS), a diversified holding company (“Hyperscale Data” or the “Company”), today announced the sale of its minority equity interest in a privately held pharmaceutical company for gross proceeds of $4.65 million in cash. Hyperscale Data purchased the equity position for $1.5 million in several closings between three and four years ago. This transaction is con ...

Gold and base metals mineralization intersected at multiple targets; exploration budget increased to support aggressive H2 programKEY HIGHLIGHTS: Chabot Target: 3.90 grams of gold per tonne (“g/t Au”) over 3.5 metres (“m”), including 9.62 g/t Au over 1 m near surface (PEN-25-100); second zone returned 2.6 g/t Au over 1.3 m with over 1% zinc (1).Alpha Target (Muskego North Shear Zone): 1.00 g/t Au over 1.0 m (MSK-25-004), confirming the down-dip extension of a 2022 bedrock sample that graded 5.18 g/t Au.Foxt ...

Kaufman Kapital exercises warrant and extends key debt maturities, providing $1 million in support of BranchOut’s financial strategyBEND, Ore., June 02, 2025 (GLOBE NEWSWIRE) -- BranchOut Food Inc. (NASDAQ: BOF), a leading food technology company specializing in its patented GentleDry™ dehydrated snacks and ingredients, announces the execution of a strategic agreement with Kaufman Kapital LLC, resulting in a $1 million cash infusion through the early exercise of existing warrants. The agreement also include ...

WALTHAM, Mass., June 02, 2025 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced that it is commencing an underwritten public offering of pre-funded warrants to purchase shares of common stock accompanied by Series A warrants to purchase shares of common stock (or, in certain circumstances, pre-funded warrants), Series B warrants to purchase shar ...

Core Viewpoint - Goliath Resources Limited is responding to strong institutional demand by initiating a concurrent non-brokered private placement alongside a previously announced bought deal private placement, aiming to raise a total of approximately C$24,065,200 [1][4]. Group 1: Offerings and Financial Details - The bought deal private placement is set for gross proceeds of C$20,002,700, while the concurrent offering aims to issue up to 1,281,545 common shares at C$3.17 each, potentially raising an additional C$4,062,500 [1][4]. - The total anticipated gross proceeds from both offerings combined is C$24,065,200 [1]. - A cash commission of 6.0% will be paid to finders for the concurrent offering, along with Finder's Warrants equal to 6.0% of the shares sold [2]. Group 2: Use of Proceeds - Proceeds from the concurrent offering will be allocated to Qualifying Expenditures related to the Golddigger-Surebet Gold Project in British Columbia, Canada [4]. - The funds will be used for exploration expenses qualifying as "Canadian exploration expenses" and "flow-through mining expenditures" under the Income Tax Act [4]. Group 3: Regulatory and Closing Information - The concurrent offering is expected to close around June 16, 2025, pending necessary approvals, including from the TSX Venture Exchange [3]. - The Charity Flow-Through Shares and associated securities will be issued under exemptions from the prospectus requirements and will be subject to a hold period of four months and one day post-closing [4].